Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
NHS National Framework Agreement for Adalimumab Injection,
Framework Period: 1 December 2018 - 30 November 2019 with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months
Tender Reference: CM/PHR/18/5567
| Supplier | Identifier | Award Value | Cross-References |
|---|---|---|---|
| Abbvie Ltd | 08004972 | £159,371,013 | LOBBYIST Policy Connect Limited (15 quarters) Portland PR Limited (3 quarters) WA Communications Ltd (3 quarters) Incisive Health Ltd (1 quarter) Political Lobbying & Media Relations Limited (1 quarter) |
| Amgen Ltd | 02354269 | £159,371,013 | - |
| Biogen Idec UK Limited | 01497267 | £159,371,013 | LOBBYIST Portland PR Limited (2 quarters) Hawthorn Advisors Limited (1 quarter) |
| Mylan | 01558756 | £159,371,013 | CH MISMATCH CF says 01558756, but CH says it's GENERICS (U.K.) LIMITED |
| Sandoz Ltd | 01547204 | £159,371,013 | - |
Government spending data: These suppliers have received £53,999,705 in 1,175 payments (over £25k) from Department of Health and Social Care, Guy's and St Thomas' NHS FT, University Hospitals Bristol and Weston NHS FT, Manchester University NHS Foundation Trust, Plymouth Hospitals NHS Trust and 9 more public bodies (2010-08-03 to 2026-03-31).